Pharmacogenetic studies of response to risperidone and other newer atypical antipsychotics
Citations Over TimeTop 10% of 2005 papers
Abstract
Risperidone and other newer atypical antipsychotics are becoming the mainstay for schizophrenia treatment. Recent studies suggest that the 5-hydroxytryptamine receptor 2A (5-HT2A) gene (HTR2A) T102C and G-1438A polymorphisms may influence treatment response of risperidone or olanzapine for schizophrenia's negative symptoms (e.g., blunted affect and social withdrawal). In addition, the HTR6 T267C polymorphism has been linked to risperidone response for positive symptoms (delusions and hallucinations). The dopamine D2 receptor (DRD2) Ser311Cys polymorphism may also play a role in determining risperidone efficacy for positive, negative and cognitive symptoms, the DRD2 Ins-A2/Del-A1 diplotype may predict better risperidone response, and the DRD3 Ser311Cys variant may affect general treatment response of several atypical agents. Although investigators have started to explore genetic effects on cognitions of schizophrenia patients receiving antipsychotics, future larger sized pharmacogenetic studies on both psychotic symptoms and cognitive functions are warranted.
Related Papers
- Comparison between the Clinical Effects of Olanzapine and Risperidone in Treatment of Alzheimer Patients with Behavioral and Psychological Symptoms(2013)
- → Cost Evaluation of Risperidone Compared With Olanzapine(2003)13 cited
- The effects of risperidone and olanzapine on the indications for clozapine.(1998)
- → RISPERIDONE AND OLANZAPNE IN-PATIENT UTILIZATION IN THE UNIVERSITY OF MALAYA MEDICAL CENTRE, KUALA LUMPUR(2006)
- Cost effectiveness analysis of olanzapine and risperidone(2009)